(Q59485638)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22101066%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

The crisis of no new antibiotics--what is the way forward? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22101066%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22101066%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Laura JV Piddock

series ordinal

1

0 references

publication date

17 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22101066%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22101066%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22101066%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22101066%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

249-253

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22101066%20AND%20SRC:MED&resulttype=core&format=json

Antibacterial resistance worldwide: causes, challenges and responses

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

The global need for effective antibiotics-moving towards concerted action

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

The urgent need for new antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Society's failure to protect a precious resource: antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Preserving the lifesaving power of antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Targeting virulence: a new paradigm for antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Multidrug-resistant gram-negative infections. Bringing back the old.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

New management of gonorrhoea. Impact of antibiotic resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Proposals seek to reduce resistance, boost development of new antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Discovery research: the scientific challenge of finding new antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Regulatory opportunities to encourage technology solutions to antibacterial drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Effective antibacterials: at what cost? The economics of antibacterial resistance and its control

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Drugs for bad bugs: confronting the challenges of antibacterial discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Sensitization of Campylobacter jejuni to fluoroquinolone and macrolide antibiotics by antisense inhibition of the CmeABC multidrug efflux transporter

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Practical applications and feasibility of efflux pump inhibitors in the clinic--a vision for applied use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Exploiting the role of TolC in pathogenicity: identification of a bacteriophage for eradication of Salmonella serovars from poultry.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Bacteriophage lysins as effective antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Medicinal plant extracts with efflux inhibitory activity against Gram-negative bacteria.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Geraniol restores antibiotic activities against multidrug-resistant isolates from gram-negative species.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Novel anti-infection agents: small-molecule inhibitors of bacterial transcription factors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Productive steps toward an antimicrobial targeting virulence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Antivirulence drugs to target bacterial secretion systems

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

A Strategy for Antagonizing Quorum Sensing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Small Molecule Inhibitors of LcrF, a Yersinia pseudotuberculosis Transcription Factor, Attenuate Virulence and Limit Infection in a Murine Pneumonia Model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Complete sequence and molecular epidemiology of IncK epidemic plasmid encoding blaCTX-M-14.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

A natural plasmid uniquely encodes two biosynthetic pathways creating a potent anti-MRSA antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in Streptomyces ambofaciens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Diagnostics as essential tools for containing antibacterial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Rapid diagnostics and appropriate antibiotic use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

The profit problem in antibiotic R&D

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Stoking the antibiotic pipeline.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Hospital and Societal Costs of Antimicrobial‐Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic Stewardship

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Strategies to contain the emergence of antimicrobial resistance: a systematic review of effectiveness and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

Treatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970316-4

7 January 2021

10.1016/S1473-3099(11)70316-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22101066%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference